79 related articles for article (PubMed ID: 1675782)
1. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
Cao H; Decker S; Stern DF
Oncogene; 1991 May; 6(5):705-11. PubMed ID: 1675782
[TBL] [Abstract][Full Text] [Related]
2. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of oncogenic and cellular p185 by serine/threonine kinases.
Dobashi K; Weiner DB; Greene MI
DNA; 1989 Dec; 8(10):723-32. PubMed ID: 2575488
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein.
Gandino L; Di Renzo MF; Giordano S; Bussolino F; Comoglio PM
Oncogene; 1990 May; 5(5):721-5. PubMed ID: 2111905
[TBL] [Abstract][Full Text] [Related]
5. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
6. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
Qian X; Dougall WC; Fei Z; Greene MI
Oncogene; 1995 Jan; 10(1):211-9. PubMed ID: 7824275
[TBL] [Abstract][Full Text] [Related]
7. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor.
Tseng CP; Verma AK
Mol Pharmacol; 1996 Aug; 50(2):249-57. PubMed ID: 8700131
[TBL] [Abstract][Full Text] [Related]
10. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
Kamps MP; Sefton BM
Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
[TBL] [Abstract][Full Text] [Related]
11. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
Bargmann CI; Weinberg RA
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
[TBL] [Abstract][Full Text] [Related]
12. 2-Aminopurine abolishes EGF- and TPA-stimulated pp33 phosphorylation and c-fos induction without affecting the activation of protein kinase C.
Mahadevan LC; Wills AJ; Hirst EA; Rathjen PD; Heath JK
Oncogene; 1990 Mar; 5(3):327-35. PubMed ID: 2107492
[TBL] [Abstract][Full Text] [Related]
13. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
[TBL] [Abstract][Full Text] [Related]
14. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
Miller P; DiOrio C; Moyer M; Schnur RC; Bruskin A; Cullen W; Moyer JD
Cancer Res; 1994 May; 54(10):2724-30. PubMed ID: 7909494
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine phosphorylation at the membrane-microfilament interface: a p185neu-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein.
Juang SH; Carvajal ME; Whitney M; Liu Y; Carraway CA
Oncogene; 1996 Mar; 12(5):1033-42. PubMed ID: 8649794
[TBL] [Abstract][Full Text] [Related]
16. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
Dougall WC; Qian X; Greene MI
J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
Sistonen L; Koskinen PJ; Lehväslaiho H; Lehtola L; Bravo R; Alitalo K
Oncogene; 1990 Jun; 5(6):815-21. PubMed ID: 1972791
[TBL] [Abstract][Full Text] [Related]
18. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
Liu SM; Carpenter G
J Cell Physiol; 1993 Nov; 157(2):237-42. PubMed ID: 7901224
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the epidermal growth factor receptor by phosphorylation.
Bertics PJ; Weber W; Cochet C; Gill GN
J Cell Biochem; 1985; 29(3):195-208. PubMed ID: 3001110
[TBL] [Abstract][Full Text] [Related]
20. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Stern DF; Heffernan PA; Weinberg RA
Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]